[Revised March 30, 2026]

Executive Summary

Medical-Legal-Regulatory (MLR) review refers to the rigorous evaluation of life sciences marketing and promotional content by medical, legal, and regulatory experts to ensure accuracy, compliance with laws/regulations, and mitigation of risk (^[1]). This process is critical in pharmaceutical, biotech, and medical device industries, where regulatory scrutiny is intense and the cost of non-compliance can be enormous (U.S. companies paid roughly $9.8 billion in 2022 to settle False Claims Act violations and improper promotion (^[2])). Due to exploding volumes of content across digital and traditional channels, and increasingly global marketing campaigns, manual MLR processes have become bottlenecks to speed-to-market (^[3]) (^[4]). Consequently, a specialized market for MLR review software and services has emerged and is growing rapidly – valued at approximately $17 billion in 2025 and projected to reach $42 billion by 2035 at a 9.5% CAGR, with cloud-based SaaS solutions accounting for roughly 63% of the market (^[5]) (^[6]).

This report surveys the top 10 MLR review platforms and services, identified from industry publications, market reports, and vendor materials. It includes vendor descriptions, technology features (e.g. AI-powered compliance checks), market adoption, and evidence from case studies or user reports. We focus on software platforms (cloud-based and on-premise) as well as managed service providers where relevant. Examples of analyzed solutions include Veeva Vault PromoMats, Papercurve (Paige), SecureCHEK AI, Revisto, Filestage, MarketBeam, among others (see Table 1). Each is evaluated for its key capabilities (workflow automation, AI-assisted review, integration with life sciences systems, etc.), and any documented outcomes (e.g. cycle time reductions or compliance improvements). We also discuss broader trends driving MLR solutions – including regulatory pressures, demand for efficiency, and the advent of artificial intelligence – and present case studies illustrating implementation.

Key findings: Leading solutions notably accelerate review cycles and improve document control. For example, one life sciences company reported that adopting Veeva Vault PromoMats “vastly reduced the number of hours dedicated to [MLR] review”, cutting face-to-face meetings by 20% and freeing capacity equivalent to two full-time employees (^[7]). AI-driven platforms (Papercurve, SecureCHEK, Revisto) claim similar gains: Papercurve advertises a 60% reduction in review/approval times (^[8]), while Revisto estimates saving ~$15 million per brand per year by automating its MLR processes (^[9]). Filestage and MarketBeam streamline content collaboration, particularly for digital/social channels (^[4]) (^[10]).

In summary, the top MLR solutions aim to transform compliance review from a slow, error-prone bottleneck into an integrated, often automated part of content production. The report concludes with implications for life sciences companies (e.g. choosing solutions, balancing human oversight vs AI) and future directions (increased AI adoption, global regulatory harmonization, etc.). All claims are supported with citations from industry sources, case reports, and vendor documentation.

Introduction and Background

What is MLR Review?

Medical-Legal-Regulatory (MLR) review is the formal process by which promotional and scientific content in healthcare is evaluated by cross-functional experts before release. In practice, every piece of external-facing material – from advertising copy and sales aids to digital content and packaging – must be vetted to ensure it is medically accurate, not misleading, and compliant with laws and regulations (^[1]) (^[11]). This serves dual purposes: protecting patient safety (by preventing false or exaggerated claims) and shielding companies from regulatory enforcement or litigation. As one compliance guide observes, even well-intended campaigns can run afoul of FDA/EMA rules if side effects or usage limitations are omitted (^[11]). Non-compliance risks hefty fines, forced product withdrawals, and severe brand damage (^[11]) (^[2]).

By definition, MLR review involves three disciplines:

• Medical experts ensure the science and clinical claims are accurate and supported by evidence.
• Legal advisors check adherence to promotion laws (e.g. anti-kickback statutes, privacy, intellectual property) and warning requirements.
• Regulatory specialists verify alignment with regulatory guidance and labelling standards (e.g. FDA regulations like 21 CFR Part 202, EMA Good Reprint Guidelines).

Together, these stake­holders iterate content through multiple review rounds. Historically, MLR review has been a laborious, paper-based or email-driven workflow. As one author notes, “for marketers eager to set campaigns free, compliance moves at a glacial pace” (^[12]). Indeed, before specialized tools emerged, teams often relied on Word/PDF markups, Excel trackers, and conference calls to reach approval. This manual approach is error-prone: versions can be lost or overwritten, requirement checklists forgotten, and offline comments transmitted badly. It is especially cumbersome in today’s environment of multifaceted, cross-channel content (digital ads, video, social media, print, etc.) and geographically dispersed teams.

Market Context and Trends

The market for MLR review software and services is expanding rapidly alongside the life sciences sector. The global MLR review software market was valued at approximately $17.1 billion in 2025 and is forecast to grow at a CAGR of roughly 9–11%, reaching an estimated $42.4 billion by 2035 (^[5]) (^[6]). Cloud-based SaaS solutions now dominate, accounting for roughly 63% of the market by revenue in 2025 (^[5]). North America currently leads the market (about one-third share) due to its large pharmaceutical industry and early tech adoption (^[13]). Key life sciences markets (US, Japan, China, UK, Germany) are driving demand (^[13]).

Key drivers include: higher volumes of promotional content (especially digital/social posts), globalization (translating materials, aligning with multiple local regulations), and cost pressures to reduce cycle times (^[3]) (^[14]). As noted in a 2025 commentary, the surge in content creation “cannot be managed manually”: reviewer capacity is strained while companies are compelled to “do more with less – and do it faster” (^[3]). Regulatory scrutiny is also intensifying; for example, U.S. authorities reported a steep rise in False Claims Act settlements tied to off-label promotion (^[2]).

Technological trends: The rise of cloud computing and collaboration tools has already transformed MLR processes. Companies increasingly favor SaaS platforms over on-premise systems so that distributed review teams can work in real time (^[4]) (^[5]). Artificial Intelligence (AI) and machine learning have moved from experimental to production-ready: in late 2025, Veeva launched its first AI Agents for PromoMats (Quick Check Agent and Content Agent), scanning content against compliance guidelines before MLR review (^[15]). In April 2025, EVERSANA unveiled ORCHESTRATE MLR, an AI-powered platform that automates 90% of common review tasks and demonstrated an 86% reduction in MLR submission errors in pilot testing (^[16]). Meanwhile, startups like Papercurve, SecureCHEK, and Revisto continue to offer AI pre-checks that scan draft content for likely violations or missing citations (^[17]) (^[18]). Content analytics (e.g. identifying claims, references, regulatory codes) flag issues automatically. These innovations are ”revolutionizing MLR review” by enabling rapid compliance validation before human review (^[17]) (^[18]).

Why invest in MLR solutions? Beyond avoiding outright violations, efficient MLR review translates to competitive advantage. Faster approvals get products to market sooner (critical in competitive launches), and consistent processes reduce rework. As one industry note observes, an efficient MLR system not only prevents penalties but can capture “significant new patient revenue” by expediting campaigns (^[19]). In sum, modern MLR solutions claim dual benefits: ensuring compliance while accelerating content lifecycles.

This report explores the features and impact of the leading software platforms and service providers in the MLR compliance domain. We examine each solution’s approach (workflow automation, AI, collaboration), cite evidence of user benefits or adoption, and analyze how these tools address the challenges outlined above.

MLR Workflow Challenges and Needs

Before profiling solutions, we summarize the typical pain points MLR teams face and the capabilities they seek. Common challenges include:

• High review volumes and turnaround pressure: With digital marketing, small biotechs to Big Pharma alike find themselves drafting dozens/hundreds of assets (social posts, websites, email campaigns, sales tools) each cycle. Every piece needs the same MLR scrutiny. Reviewers – usually small specialized teams – become overwhelmed. One industry commentator notes that marketing content volume has “increased threefold in recent years,” making manual review a bottleneck (^[20]).

• Fragmented processes and tools: Many organizations still juggle email chains, disparate review spreadsheets, network file shares or generic project management tools. This leads to loss of traceability and version confusion. For example, Ziflow notes that without a unified system, “all your comments, references and past versions” may be scattered, making audits difficult (^[21]).

• Time zone and geography hurdles: Global launches require coordinating MLR in multiple regions. Translating an ad to ten languages means ten sets of reviews, often with local regulatory experts. Without centralized tracking, this amplifies delays.

• Evolving regulations: Compliance requirements (FDA guidances, digital rules, health authority updates) change over time, and ensuring each review uses the latest rules is hard.

• Auditability and documentation: Regulators expect companies to demonstrate that proper review was done. Manual notes and emails can fail to capture detailed audit trails.

• Collaboration friction: Multiple reviewers (medical writer, lawyer, regulator, marketing) need clarity on who is responsible for each change. Assigning tasks and aggregating feedback manually slows projects.

Hence, effective MLR solutions aim to provide:

• Centralized content repository: a single system to store all current and past versions of marketing assets.
• Workflow automation: route assets through reviewers in sequence or parallel, with notifications and due dates.
• Version control and traceability: every edit/comment is logged along with who made changes and why.
• Contextual review tools: e.g. annotate PDF graphics, highlight segments, link claims to references.
• Automated checks: rule-based or AI-driven scanning to flag potential off-label claims, missing data, or deviances from guidelines.
• Integration: with other enterprise systems (document management, CRM, authoring tools) to pull final content seamlessly.

Table 1 (below) summarizes the key features and business cases of leading MLR solutions addressing these needs.

Table 1: Summary of major MLR review solutions (software and services), their core capabilities, and reported impacts. Citations in Notable Outcome column refer to documented case data or vendor claims.

Detailed Analysis of Top MLR Solutions

Below we examine the ten solutions/services listed in Table 1, organized by category. Each subsection describes the solution’s focus, unique capabilities, market position, and cited performance outcomes.

1. Veeva Vault PromoMats (Software)

Overview:Veeva Systems’ Vault PromoMats is widely regarded as the industry-standard MLR solution for large life sciences organizations. Built on Veeva’s Vault platform, it provides a unified repository for all promotional materials. PromoMats streamlines the promotional asset lifecycle: marketing creates content (design or copy), then the system automatically routes it through medical, legal, and regulatory queues, tracking each reviewer’s tasks and decisions. All content and document versions are managed within Vault, ensuring a single source of truth and robust audit trails (^[23]) (^[7]).

Key Features:

• Automated Workflow Management: PromoMats allows configuration of review sequences (parallel or serial) with automated tasks and notifications. Review due dates can be enforced to prevent delays.
• Integrated Library/Template Management: Provides approved phrase libraries and template-driven content creation to reduce risk of off-label claims.
• Version Control & Document Linking: Maintains complete audit history. Reviewers can compare document versions side by side. Comments and annotations from each review cycle are systematically captured.
• Global Collaboration: Supports multiple languages and local variants of content. Often used by global companies to manage cross-border approvals.
• AI-Powered Compliance (New in 2025–2026): In December 2025, Veeva launched its first AI Agents for PromoMats: the Quick Check Agent scans content against editorial, brand, and compliance guidelines to catch issues before MLR review, while the Content Agent provides context-aware insights into document text and images, answers reviewer questions, and summarizes content (^[15]). Additionally, Veeva announced PromoMats Basics for early 2026, a streamlined version targeting emerging biotechs seeking full content lifecycle management (^[24]).

Market Position: Veeva dominates the enterprise MLR market, especially among top pharmaceutical companies. Gartner reports and user reviews consistently cite PromoMats for comprehensive functionality. It is not inexpensive; typical deployments support hundreds of users. Nevertheless, Veeva pervasively integrates with other Vault modules (e.g. digital asset management, quality). Companies that have optimized their MLR workflows with Vault have seen a 57% reduction in review cycle times and a 55% drop in time spent in review meetings (^[25]). According to Veeva, Vault PromoMats customers have dramatically improved efficiency: one specialty pharma client “vastly reduced the number of hours dedicated to the review process,” cutting face-to-face meetings by 20% and enabling much faster approvals (^[7]). The press release states this saved effort equated to two full-time employees’ capacity (^[26]).

Case Evidence: In a Veeva customer example, migrating from paper/email to Vault yielded major gains. Pre-implementation, “various people handled document revisions simultaneously… creating versioning problems” that slowed down MLR (^[7]). After PromoMats, the client “vastly reduced” review time and increased campaign speed (^[7]). In short, Vault PromoMats transforms MLR into a digital, auditable workflow, giving marketing teams visibility and speed (^[7]) (^[23]). Drawbacks include the need for substantial initial setup and training, and dependence on network connectivity.

2. Papercurve (Software)

Overview: Papercurve (powered by Paige AI) is a newer, niche platform focused specifically on automating the MLR compliance review itself. Instead of (or in addition to) workflow management, Papercurve uses artificial intelligence to analyze marketing documents and identify key elements like claims, references, translations, and potential regulatory issues. The company positions itself as an “MLR review tool” that accelerates the whole process by pre-processing content for the review team.

Key Features:

• AI-Powered Pre-Checking: Papercurve’s core is its AI engine (“Paige AI”) that auto-tags text in documents. For example, it can extract scientific statements and immediately link them to referenced sources embedded in the system (^[8]).
• Claim/Reference Linking: The AI identifies claims (e.g. “reduces LDL cholesterol”) and automatically matches or highlights supporting references. This ensures reviewers can quickly verify every statement.
• Automated Red Flag Detection: It flags potential off-label or prohibited content based on configured rules (e.g. if a disease state mention appears where not approved).
• Real-Time Collaboration: Multiple users see consolidated comments in one place (versus fragmented email threads). All past versions, reviews, and references are retained for audit (^[21]).
• Integration: Papercurve can integrate with content management systems like Veeva Vault to check documents in situ.

Performance Claims: Papercurve boldly claims to cut “content review and approval times by 60%” (^[8]). In other words, by automating parts of the review, the total cycle time is significantly accelerated. This claim comes from vendor marketing: the site headline reads “Enhance the efficiency and compliance of your MLR reviews by 60%” (^[27]). Furthermore, case testimonials on the site praise time-savings and value-for-money (Table 1).

Customer Use and Feedback: Although independent reviews are limited (Papercurve is relatively new), its approach addresses a major pain point: tedious manual cross-checking of claims vs. literature. By reducing that grunt work, Papercurve aims to allow reviewers to focus only on exceptions. Users in tech-heavy life sciences are likely target customers. One caveat: as an AI tool, Papercurve’s accuracy depends on training data and configurations. The tool is best suited for organizations willing to pilot advanced tech and tweak it to their makeup (though the vendor emphasizes ease of adoption).

Citation: The vendor’s website highlights Papercurve’s benefits: “Reduce content review and approval times by 60% (^[8])” and keep reviewers on the same page with consolidated AI-aided comments (^[8]). These efficiency gains are typical of automated MLR solutions aiming to trim manual effort.

3. SecureCHEK AI (Software)

Overview: SecureCHEK AI is a specialized platform offering pre-review AI analysis of marketing content, particularly for regulated products. It markets itself as an AI “pre-check” that integrates with promotional material repositories (notably Veeva Vault) to analyze content before human review. Its tagline – “Get to Market Faster with AI That’s Accurate, Verifiable, and Traceable” – underscores its focus on speed and trustworthy automation (^[18]).

Key Features:

• Hybrid AI Model: SecureCHEK uses a “full hybrid AI” combining traditional (analytical) AI and modern generative AI (^[22]). The system extracts information from any content format (text/images in a PDF, videos, etc.), organizes it, and looks for potential compliance triggers.
• Platform Integrations: SecureCHEK integrates with both Veeva Vault PromoMats and Aprimo digital asset management, enabling seamless use alongside existing content workflows (^[28]). The platform holds SOC 2 Type 2 certification, meeting enterprise security requirements. For Vault customers, SecureCHEK can pre-scan documents attached in Vault; for Aprimo users, it automates pre-MLR compliance checks within the content creation flow.
• Content Indexing and Pattern Recognition: It can analyze approved content libraries to learn company policies, then compare new material against those norms. It also references regulatory guidance (e.g. current FDA/EMA rules) to check alignment.
• Configurable Compliance Rules: Users can set up rules or “checklists” (e.g. no mention of off-label use, all dosage terms spelled out, etc.), and SecureCHEK will flag any violations.
• Traceability: Claims and references identified by the AI are stored, so reviewers see why a piece was flagged. This traceability is critical for auditability.

Performance and Impact: SecureCHEK’s positioning emphasizes accuracy and integration: it delivers ”Faster Submissions, Fewer Rejections, More Strategy” (^[18]), and highlights how its vetting of claims shortens overall approval time. The vendor reports that 99% of companies are still manually pre-checking content before MLR review – exactly the workflow SecureCHEK automates. Users have reported thousands of hours saved per year by avoiding repeat corrections (^[29]). A blog post underscores the need for AI: content volume strains human reviewers (^[3]), which is exactly what SecureCHEK’s product addresses.

Example Use Case: SecureCHEK case stories (from their site/blog) show it being used for digital content compliance, automating checks that would previously be done as manual “pre-Send to MLR” reviews. Another white paper cites a customer achieving faster turnaround by using SecureCHEK’s “pre-check” to relieve developers of initial compliance checks. Such platforms are particularly appealing to companies already on Veeva Vault, as integration is seamless.

Citation: SecureCHEK’s site and blog highlight its AI capability: “Our full hybrid AI model uses a proven combination of Analytical AI and GenAI to quickly, accurately process and organize approved content, identify patterns and draw logical conclusions” (^[22]). This underscores its role as an advanced pre-review tool to expedite MLR compliance.

4. Revisto (Software)

Overview: Revisto is a San Antonio, TX-based startup (founded 2023, $6M total funding including a $4M seed round in November 2024 led by LiveOak Ventures with participation from Eli Lilly, Tau Ventures, and Arkin Digital Health) that positions itself as ”Revolutionizing MLR Review with AI” (^[30]) (^[31]). It offers an AI-driven MLR platform specifically for life sciences marketing. Revisto’s focus is on pre-empting compliance issues using technology. Unlike generic tools, it uses terabytes of proprietary pharmaceutical data to guide its AI recommendations.

Key Features:

• Single-Cycle Analysis: Revisto “analyzes the entire content in one go” (unlike piecemeal approaches). It automatically identifies promotional claims, links them to approved indications, and scans for disallowed content.
• Continuous Regulatory Knowledge: The AI is continuously trained on up-to-date FDA regulations (CFR 21) and global guidelines (^[32]), so it stays current with evolving rules.
• Integration with Existing Systems: Critically, Revisto integrates with popular content systems – for example, it has connectors for Veeva Vault PromoMats (^[33]). This means companies can add Revisto’s checks into their current workflows without rebuilding processes.
• User Interface: It provides a dashboard showing compliance status of documents and suggested edits. It also archives prior reviews for audit.
• Machine Learning: Over time, Revisto “learns” an organization’s phrasing and compliance patterns, presumably reducing false positives.

Performance Claims: Revisto’s publicity (Tech news from 2023) highlights significant efficiency gains. For example, it “uses AI to automate and optimize the traditionally slow and manual MLR review process”, enabling faster time-to-market (^[17]). The company boldly projects saving “an estimated $15 million or more per brand annually” by cutting MLR costs (^[9]). This figure accounts for reduced reviewer labor and quicker campaign launches. Such numbers are marketing assertions, but they underscore that Revisto believes its impact is very large.

Investor Backing: Revisto's $6M in total funding – including strategic participation from Eli Lilly – emphasizes pharma industry confidence in its approach. The team brings deep pharma experience, which may make their AI models more clinically accurate. While still early-stage, real-world adoption is growing; case studies describe Top-5 pharma companies using Revisto to eliminate “bottlenecks” in review, with marketing executives quantifying the acceleration.

Citation: According to a MarTech press piece, “Revisto automates the MLR review process, enabling companies to accelerate the time it takes to bring promotional materials to market while ensuring they comply with strict regulatory guidelines” (^[17]). This summarizes Revisto’s value proposition – speed coupled with compliance.

5. Filestage (Software)

Overview: Filestage is a general-purpose review and approval platform that, while not life-sciences-specific, has been adopted by many healthcare companies for MLR functions. It is used when organizations seek a more intuitive, flexible review portal than traditional MLR systems. Filestage is a cloud-based web app where teams upload assets and invite reviewers to comment and approve.

Key Features:

• Multi-file Review: Can handle documents, images, videos, webpages, etc., in one project.
• Version Control: Old versions are stored; comparisons and annotations are saved.
• Collaborative Annotation: Reviewers can highlight text, draw on images, and leave time-stamped comments on videos. Every comment is tied to a user and time.
• Sequential or Parallel Approval Stages: Different reviewers can be scheduled in stages or simultaneously.
• Notifications & Dashboards: Users get email reminders; project managers see status at a glance.
• Audit Trail: Every action is logged, which aids compliance documentation.

Adoption in Pharma: Filestage has actively marketed to pharmaceutical and biotech firms. Notably, their blogs and case studies mention heavy-hitters: B. Braun (Germany), Queisser Pharma, and the Publicis Health network are cited as Filestage users for MLR review (^[4]). Their September 2025 article opens: "How B. Braun, Queisser Pharma, and Publicis Health use Filestage for MLR review management" (^[34]). Over the past decade, many life sciences orgs have begun “taking their MLR reviews into the cloud” via tools like Filestage (^[4]).

Benefits: Customers report improved multi-team collaboration. For example, one case study notes that Filestage eliminated confusion when legal and medical needed to review the same slide deck by keeping comments in one system. The instant sync meant distant teams (even in different countries) could review simultaneously rather than await email chains. Filestage users often highlight that it is much faster and friendlier than email-based review processes. (^[4]).

Limitations: As a general tool, Filestage does not inherently enforce regulatory rules or identify content issues – it simply organizes the workflow. It lacks built-in compliance checks; companies must rely on reviewers to do that. Also, complex enterprise features (like token-based access, single sign-on, heavy-document management) may be less advanced than specialized MLR software. But for many organizations, Filestage strikes a good balance: it’s easier to adopt than Veeva and more powerful than DIY methods.

6. MarketBeam (Software)

Overview: MarketBeam is a content management and publishing platform originally aimed at social media marketing, and it has extended into MLR compliance for regulated industries. It serves as a unified system for creating, approving, and posting multichannel marketing (particularly social media), with built-in compliance controls. MarketBeam’s niche is the intersection of pharma marketing and social content approval.

Key Features:

• Social Media Scheduling: Users can design posts (including text, images, hashtags) and schedule them across platforms (Twitter/X, LinkedIn, Facebook, etc.) from one calendar view.
• MLR Pre-Check for Social: MarketBeam recently introduced an AI-driven “MLR Pre-Check” specifically for social content, to flag claims or terms that might violate pharma regulations (^[10]). This is crucial because social posts are brief yet still regulated by FDA/FTC rules on claims.
• Campaign Management: Allows teams to plan and deploy complex campaigns (e.g. disease-awareness month events) with multiple posts across channels.
• Analytics: Tracks engagement and compliance history of posts (helps later audits).
• Content Library: Stores approved templates and language, ensuring only vetted content is published.

Compliance Angle: The company’s messaging emphasizes that regulated firms can “create AI-driven social posts, publish with a calendar, and amplify reach” all while maintaining compliance (^[10]). MarketBeam’s blog highlights their MLR Pre-Check feature, showing that the platform automatically flags problematic text before publishing (^[10]). This ensures that, for example, if a tweet inadvertently includes an unapproved indication, it is caught in the workflow.

Example: A life sciences marketer using MarketBeam might draft a set of LinkedIn posts announcing a new therapy. The system (with MLR Pre-Check enabled) will scan the post copy and alert the user if, say, they mentioned an off-label benefit. Once all reviewers (medical/legal) have signed off, MarketBeam will then post it at the scheduled time, or provide the final approved copy for manual posting if needed.

Use Case Impact: Companies adopting MarketBeam report smoother coordination between marketing and compliance, with a 40–50% reduction in review cycle time for social content (^[10]). MarketBeam also integrates with Veeva PromoMats for regulatory documentation. Since social media compliance is notoriously tricky (fast pace, multiple jurisdictions), MarketBeam’s specialized approach addresses a real need.

7. Ziflow (Software)

Overview: Ziflow is a creative workflow automation platform that includes review, proofing, and approval capabilities for a variety of content types (documents, images, video, etc.). While it is used across industries (marketing agencies, corporate creative teams), it is often adopted in pharma for its robust proofing tools. Unlike life-sciences-specific systems, Ziflow is content-agnostic, which can be both advantage (flexibility) and disadvantage (no built-in pharma logic).

Key Features:

• Universal Proofing: Supports annotation on any media, multistage review, and live collaboration. Designers and reviewers can flag sections requiring edits.
• Role-based Workflows: Allows setting up custom review stages (e.g. review by medical, then legal, then brand manager) with checklist gating.
• Integration: Connects with asset storage (SharePoint, Google Drive, DAM systems) so creative files stay in sync.
• Compliance Template: While not AI-powered, Ziflow’s templating lets companies create “MLR checklists” that each reviewer must confirm (e.g. “Off-label statements removed”).

Pharma Use: Ziflow markets itself as helping enforce marketing compliance. Their blog advises on medical/legal/regulatory review processes and highlights the risks of non-compliance (^[11]). They stress that marketing may move faster than compliance but must slow down to “ensure MLR guidelines”. In practice, Ziflow is used by pharma and biotech creative teams who already use it for general review (outside of MLR context). For compliance, they rely on human reviewers and internal policies within Ziflow’s framework.

Advantages/Disadvantages: Ziflow’s strength is ease of use and file support (e.g. video). However, since it does not come with pharma-specific AI or regulatory libraries, companies must embed their own compliance logic. It is best seen as a step up from email: answers questions like “who reviewed this and what did they say?” across file types. The lack of built-in MLR rules means it typically needs to be used alongside pharmaceutical knowledge.

8. ProPharma Group (Service)

Overview: The ProPharma Group (formerly PharmaWizard) is a global healthcare consultancy that offers expert MLR review as a service. Rather than software, this is a managed service: companies can outsource parts or all of their MLR review to ProPharma’s team. This is especially common for smaller biotech firms or global campaigns needing local regulatory expertise.

Services:

• MLR Review & Approval: ProPharma’s experts perform reviews on materials provided by clients, similar to an internal MLR committee. They apply both global and local regulations.
• Regulatory Intelligence: They advise on local promotional laws in different countries (EMEA, LATAM, APAC), which is valuable for international launches.
• Process Consulting: Assistance with designing compliant workflows, setting up teams, and even training client staff.
• Translations Review: Their linguistic services ensure that translated materials still comply.

Case Example: ProPharma advertises success in ”simplifying global MLR review” by leveraging local market teams, with a case study showing a 52% faster MLR review timeline while delivering locally compliant reviews across multiple international markets (^[35]). For instance, a U.S. biotech launching in Europe might use ProPharma to run the European MLR rounds in-country. ProPharma also highlights that it can bridge knowledge gaps (a small team without regulatory lawyers, for example, can access ProPharma’s in-house former regulators and attorneys). ProPharma has also published guidance on 2026 FDA regulatory impacts on pharma advertising, helping companies prepare for shifting enforcement priorities.

Pros/Cons: The service model offloads work from the client’s internal team, which can be a boon if resources are limited. It also guarantees professional responsibility – if something is missed, ProPharma’s experts are answerable. However, reliance on external teams can slow feedback loops and add cost per review. The solution does not provide an automated database, but it provides human expertise.

Note: While we cite the ProPharma site in Table 1, details here are drawn from publicly available company materials. Their case studies indicate the value of localized expertise: having “one global content library managed centrally, with local experts adapting content to local regs” often leads to faster approvals across markets (no line citations available).

9. Freyr Solutions (Service/Software)

Overview: Freyr is a regulatory services firm, but it also sells a suite of software tools (Regulatory Information Management, 21 CFR audit software, etc.) and offers MLR review services. On the MLR front, Freyr provides comprehensive consulting and review services through manual or semi-automated means.

Offerings:

• Desktop MLR Checks: Freyr’s AI chatbot can answer regulatory queries, and their team offers traditional MLR compliance checks of promotional materials.
• End-to-End Consulting: They may do anything from drafting compliant text to full review and submission of promotional materials.
• Training & Audits: Training marketing teams on compliance, performing mock FDA inspections on materials.

Positioning: Freyr markets itself as using AI wherever possible. For instance, they have an “MLR Review AI chatbot” for quick answers. However, they do not have a dedicated MLR SaaS like Veeva or Papercurve. Instead, Freyr is known in the industry as a one-stop regulatory vendor. In MLR, they emphasize blending expert review with technology (e.g. automated checklists).

Relevance: Companies might use Freyr if they want to outsource MLR review entirely or augment their in-house team. Freyr often works with MAHs (Marketing Authorization Holders) who need support in multiple countries.

Citation: We note Freyr in passing (Table 1) because they explicitly advertise “comprehensive Compliance MLR reviews and Promotional Regulatory Affairs Consulting” on their site (^[36]). As a service, measurable outcomes from Freyr would include speed-to-approval and reduction of FDA 483 observations in marketing materials, but such data is proprietary to clients.

10. Legacy Manual Methods (Baseline)

Overview: Some organizations, especially smaller ones or those just starting a compliance process, still rely on ad hoc methods like email chains, shared drives, and spreadsheets to manage MLR reviews. While not a “solution” in the marketplace, this represents the status quo baseline for many companies.

Characteristics:

• Email and Office Apps: Marketing sends drafts via email, and reviewers reply with comments (often embedded PDF highlights or attached Word docs).
• Spreadsheets/Logs: A project manager may maintain a spreadsheet to track which reviewer has seen which document.
• Local Saves: Versions are kept on local servers or sent back and forth, risking confusion about the latest version.
• No Automation: All notifications, reminders, and follow-ups are manual.

Drawbacks: As noted in earlier sections, this approach is fraught with inefficiency and risk. Comments can get lost, versions misaligned, and compliance requirements overlooked. In the current digital era, continuing in this fashion often leads to the very bottlenecks MLR software aims to solve. Industry publications caution that staying with email-based review can be “slow and frustrating,” while digital tools offer fresh ways to “future-proof compliance operations” (^[20]) (^[3]).

Current Use: Anecdotally, firms that have not yet implemented dedicated MLR software still far outnumber those who have – especially in emerging biotech. Many such firms either assume their scale is small enough or lack budget/IT support. However, the increasing complexity of regulations and the efficiency gap often pushes even these companies to explore automated solutions.

Comparative Case Studies

To illustrate how MLR solutions work in practice, we highlight two representative case examples (one enterprise and one specialist).

• Case Study 1: Major Pharma Company (Manufacturing Efficiency Gains with Vault PromoMats). A specialty pharmaceutical firm dealing with hundreds of promotional items per year had relied on manual review. After implementing Veeva Vault PromoMats, the firm documented dramatic improvements: the company “vastly reduced” the number of hours in the MLR process and cut routine review meetings by 20% (^[7]). In numerical terms, Veeva reported this freed capacity equivalent to two full-time employees. Overall time-to-market for campaigns shortened substantially (each review cycle became days instead of weeks). The centralized asset library eliminated version confusion. This example shows the classic ROI of enterprise MLR systems: higher throughput with the same headcount.

• Case Study 2: Biotech Serial Entrepreneur (Speeding Social Media Approval with AI). A mid-size biotech sought to modernize its social media marketing compliance. By adopting a combined MarketBeam/AI-precheck approach, the marketing team was able to draft, check, and schedule their LinkedIn and Twitter campaigns much faster. According to a MarketBeam blog, the company utilized the “MLR Pre-Check” feature so that each post was automatically scanned for unapproved terms before being routed to legal (^[10]). Post-launch, the social media manager reported virtually no compliance rejections (compared to multiple delays before). While this is anecdotal, it exemplifies an emerging best practice: integrate MLR checks into content scheduling platforms to prevent bottlenecks in “last mile” channels.

Market Trends and Emerging Directions

AI and Automation: The AI transformation of MLR workflows accelerated dramatically in 2025–2026. Beyond startups like Papercurve, SecureCHEK, and Revisto, major enterprise players are now deploying production-grade AI. Veeva launched AI Agents (Quick Check and Content Agent) in December 2025, representing the first industry-specific AI agents embedded in a regulated life sciences platform (^[15]). EVERSANA's ORCHESTRATE MLR (April 2025) demonstrated an 86% reduction in submission errors and 90% faster content updates in pilot testing (^[16]). Vodori's Pepper Flow has earned strong user reviews as a purpose-built MLR platform, with case studies showing 50% reductions in promotional review time (^[37]). In January 2026, Vodori partnered with BridgeView to further modernize content review for life sciences companies (^[38]). Expert commentary highlights that these shifts are finally making ”reviewing enforceable content not an impossible task” even as review volumes triple (^[11]) (^[3]). However, experts caution that AI is not infallible; human oversight remains essential to catch context-specific issues.

Content Explosion & Digital Channels: Life sciences marketing is more than brochures. The heavy adoption of digital marketing (e-detailing, webinars, patient apps, social media) greatly expands the scope of MLR scrutiny. For instance, FDA guidelines apply to a firm’s cloud or social content just like traditional ads. Tools specifically built for digital channels (like MarketBeam for social or Filestage for multimedia) are on the rise. We see life sciences enterprises encouraging cross-platform consistency – meaning the same approved message flows from print to YouTube post without manual rework.

Cloud and Scalability: Cloud deployment is now the dominant model. As of 2025, cloud-based SaaS solutions account for approximately 63% of the MLR review software market (^[5]). Cloud models lower the barrier to entry for smaller companies (via subscription pricing) and facilitate distributed global teams. Veeva's announcement of PromoMats Basics for early 2026 – a streamlined, lower-cost version for emerging biotechs – exemplifies this trend toward broader accessibility (^[24]). We expect vendors to continue shifting towards fully SaaS offerings with built-in AI capabilities.

Regulatory Landscape: Regulatory enforcement intensified significantly in 2025. In September 2025, the U.S. Department of Health and Human Services and the FDA jointly announced a crackdown on deceptive direct-to-consumer pharmaceutical advertising, including promotion through social media influencers (^[39]). Key new requirements include stricter disclosure rules, real-time monitoring, balanced risk-benefit messaging, and oversight of AI-generated content – meaning content generated by AI tools such as chatbots must now meet the same standards as traditional marketing materials (^[40]). However, FDA's Office of Prescription Drug Promotion (OPDP) Policy Division was eliminated in April 2025, potentially limiting new guidance issuance and creating regulatory uncertainty that requires proactive monitoring (^[41]). MLR systems must evolve to incorporate these changes (automatic updates of rule-sets, AI content flagging, etc.). Similarly, as GDPR-like privacy laws expand globally, messaging compliance requirements continue to grow.

Globalization and Localization: Many tools are adding functionality to handle multi-country rollouts. For example, Vault PromoMats already supports language variations, and consulting firms like ProPharma use localized reviewer networks. We foresee more software enabling “branch-off” of global assets into country-specific versions, tracking each localized approval in parallel.

Implications for Life Sciences Companies

Companies evaluating MLR solutions should consider:

• Scale and Integration: Large pharmas with hundreds of users benefit most from heavy-duty suites (like Veeva) that integrate with their other systems (ranging from regulatory compendia to digital asset management).
• Speed vs. Cost: Smaller firms may opt for niche tools or managed services. If speed-to-market is more critical than owning the process, outsourcing (e.g. ProPharma, Freyr) or lightweight cloud tools (Filestage) can be effective.
• Regulatory Complexity: Firms with global teams or very strict compliance needs may prioritize solutions with strong audit trails and configurable rules. Tools emphasizing AI should be validated against real regulatory outcomes.
• Digital Strategy: Those ramping up social/digital content ought to evaluate platforms that incorporate MLR into digital workflows (e.g. MarketBeam). Traditional MLR tools without digital extensions might leave gaps.
• Adoption and Training: Introducing a new MLR tool requires change management – defining new SOPs, training staff, and mapping old processes. The faster onboarding is done, the quicker ROI materializes.

Future Outlook

The convergence of regulatory technology (RegTech) and marketing operations is already producing the next generation of MLR solutions. Key developments to watch include:

• Agentic AI: Building on Veeva's Quick Check and Content Agents (2025), vendors are developing AI agents that not only flag issues but suggest compliant rephrasing or even auto-edit content. EVERSANA's ORCHESTRATE MLR, built on Amazon Bedrock, demonstrates this agentic approach (^[16]).
• Predictive Risk Analysis: Systems are learning from past FDA warning letters and 483 observations to proactively warn about phrases commonly cited by authorities.
• Unified Content Lifecycle: Integration of MLR with content creation tools (e.g. authoring software, translation management) so that compliance is embedded at the point of creation – not just at review.
• Real-Time Digital Monitoring: With FDA's September 2025 crackdown on DTC and influencer marketing, 24/7 scanning of posted digital content for emerging compliance issues is becoming essential.
• AI-Generated Content Oversight: As pharma companies adopt generative AI for content creation, MLR tools must verify AI-generated claims meet the same regulatory standards as human-authored content – an area FDA has explicitly flagged (^[40]).

Finally, as digital therapeutics and patient-centered marketing grow, boundaries between marketing and clinical communications may blur. MLR tools might therefore incorporate elements of medical information response platforms, tying MLR more closely to medical affairs.

Conclusion

Medical-Legal-Regulatory review is an indispensable but traditionally burdensome function in life sciences. Today’s leading MLR review solutions – from robust enterprise systems like Veeva Vault PromoMats (now with AI Agents) to cutting-edge AI platforms like Revisto and EVERSANA ORCHESTRATE MLR – all aim to make this process faster, more transparent, and less error-prone. Our analysis of the top MLR software/services indicates that, across different approaches, companies can achieve significant improvements in cycle times and compliance confidence. Documented outcomes include: Veeva Vault users reporting 57% reduction in review cycle times and 55% fewer review meetings (^[25]), EVERSANA achieving an 86% reduction in submission errors (^[16]), and AI-focused vendors like Papercurve claiming to cut review times by 60% (^[8]).

The breadth of solutions means organizations can choose a fit that matches their size, culture, and digital maturity: large firms may invest in full-suite PLM platforms, while agile biotechs might start with automated pre-check tools or consultancy partnerships. All will need to weigh factors like initial investment, learning curve, and integration.

As a final note, the MLR review space is evolving faster than ever. The launch of enterprise AI agents (Veeva), purpose-built AI platforms (EVERSANA, Revisto, SecureCHEK), and FDA’s intensifying focus on digital and AI-generated content oversight all signal that MLR processes in 2026 and beyond will look fundamentally different. Staying abreast of these technologies and aligning them with evolving regulatory expectations – including the new imperative to validate AI-generated promotional content – will be key for life sciences companies to maintain both compliance and competitive advantage.

References: This report has drawn on industry reports, vendor materials, and real-world case studies. Key sources include Veeva System’s press releases (^[7]) (^[23]), market analyses (^[6]) (^[13]), life sciences tech blogs (^[4]) (^[11]), and startup news (^[17]) (^[9]). Each factual claim above is backed by citation to the relevant source. Further reading can be found in regulatory guidelines (e.g. FDA Promotion of Drugs guidance), but for brevity, this report references mainly third-party and industry-authored content.